1. Number of patients with acute & subacute toxicity based on CTCAE scoring system v4.03 (Time Frame - from the beginning of radiotherapy until 90 days after the end of the treatment)
Secondary outcome:
1. Number of patients with late Toxicity based on CTCAE scoring system v4.03 (Time Frame - beginning from 91 days after the end of radiotherapy until the end of the 2 years follow up)
2. Change from baseline quality of life(QoL)using EORTC QLQ-C30 v3&EORTC QLQ-H&N43 modules(Health related QoL specific for Head&Neck ca.)scores at end of RT, 3,12&24 months after RT.Swallowing (H&N43:4-item scale)3 months after RT is the primary QoL domain (Time Frame - up to 24-28 months depending on the treatment duration.): EORTC QLQ-C30 and H&N43 will be used
3. Loco-regional control (Time Frame - 2 years from the randomization)
4. Progression-free survival (Time Frame - 2 years from the randomization)
5. Overall survival (Time Frame - 2 years from the randomization)
6. Distant metastasis-free survival (Time Frame - 2 years from the randomization)
7. Disease-specific survival (Time Frame - 2 years from the randomization)
8. QoL comparison between the patients who accepted to be randomized (into rA and rB) and not (into oA and oB: in other words, patients who chose their own treatment strategy) (Time Frame - Baseline QoL and until the end of 2 years follow-up)
9. Surgical complication rates (Time Frame - 2 years from the randomization)
10. Rate of Isolated nodal control (Time Frame - 2 years from the randomization): The absence of metastatic lymph node metastases in the neck without any synchronous or preceding local recurrence or distant metastases
11. Radiation dose and volumes (Time Frame - until the end of radiotherapy, expected to be on average 7 weeks): The dose-volume histograms of all organs-at-risk (defined per protocol) will be compared between patients with and without up-front neck dissection. The doses will be reported in Gy and the volumes in cc.
12. Comparison of applied RT plan and the virtual RT plan done on the pre-UFND diagnostic CT images (Time Frame - until the end of radiotherapy, expected to be on average 7 weeks): The dose-volume histograms of all organs-at-risk (defined per protocol) will be compared between the plans generated based on the pre- and post-UFND CT-scans of patients allocated the UFND arm. The doses will be reported in Gy and the volumes in cc.
13. Comparison between clinical and pathological stages of patients allocated to the UFND arm. according to the AJCC/UICC TNM staging system (7th edition). (Time Frame - until the generation of the definitive pathology report after the up-front neck dissection, expected to be within 3 weeks after patients' study enrollment)
Active Comparator: Arm rA (randomized) Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
Experimental: Arm rB (randomized) Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
Active Comparator: Arm oA (non-randomized) Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
Experimental: Arm oB (non-randomized) Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
radiotherapy: 70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
Chemotherapy (Cisplatin): 100 mg/m2 every three weeks during radiotherapy
In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension.
Early Salvage Neck Dissection in case of less than cCR (Arm A only): Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.
In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!